United States Actinic Keratosis Treatment Market Size Insights Forecasts to 2033

• The U.S. Actinic Keratosis Treatment Market Size was valued at USD 2.39 Billion in 2023.
• The Market Size is growing at a CAGR of 2.99% from 2023 to 2033
• The U.S. Actinic Keratosis Treatment Market Size is expected to reach USD 3.21 Billion by 2033

The United States Actinic Keratosis Treatment Market is anticipated to exceed USD 3.21 Billion by 2033, growing at a CAGR of 2.99% from 2023 to 2033. The growing incidence of actinic keratosis, the increasing innovative medications usage, and the geriatric population in the region are driving the growth of the actinic keratosis treatment market in the US.     

Market Overview

Actinic keratosis also known as sun keratosis or senile keratosis, is a pre-cancerous skin condition that results in scaly, rough, or crusty patches or lumps. Actinic keratosis is the most frequent pre-cancerous dermatological condition, with 5-10% of cases progressing to squamous cell carcinoma. According to a study published in JAMA Dermatology, actinic keratosis affects around three out of every ten older Medicare recipients. Home-based therapies with topical preparations, cryotherapy, and PDT are common techniques for treating actinic keratosis. Further, several new agents are in development to decrease undesirable effects. Resiquimod, betulinic acid, paclitaxel, potassium dobesilate, potassium hydroxide, and celecoxib are among the new medications being studied for AK, according to the National Institutes of Health. These therapeutic medications are intended for customized treatment of patients with AK lesions and cutaneous SCC symptoms. The continuous efforts to create next-generation treatments for various dermatological conditions, including AK, basal cell carcinoma, and atypical moles, are projected to provide lucrative market opportunities.   

Report Coverage

This research report categorizes the market for the US actinic keratosis treatment market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States actinic keratosis treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US actinic keratosis treatment market.

Driving Factors

According to the American Academy of Dermatology Association, approximately 40 million Americans develop AK each year, with the overall prevalence rate in the United States estimated to be 26.5% in men and 10.2% in women. Thus, the increased prevalence of actinic keratosis leads to drive the market. Higher rates of actinic keratosis treatment and increasing innovative medications usage in the country, together with beneficial activities from non-profit organizations to prevent actinic keratosis are responsible for driving the market growth. Actinic keratosis is a significant public health issue among older persons in the United States. Thus, the increasing geriatric population is contributing to driving the market demand for actinic keratosis treatment. The presence of potential investigational candidates in the pipeline and increased R&D activities by pharmaceutical companies to discover novel treatment techniques for actinic keratosis are likely to contribute to market expansion.

Restraining Factors

The loss of patent exclusivities of most of the treatment options in the US leads to genericization that may impede market growth. Further, strict regulatory frameworks relating to the safety and efficacy of pharmaceuticals may hamper the market for actinic keratosis treatment.

Market Segmentation

The United States Actinic Keratosis Treatment Market share is classified into therapy, drug class, product, and end-use.

• The surgery segment dominates the US actinic keratosis treatment market with the largest share in 2023.

The United States actinic keratosis treatment market is segmented by therapy into topical/drugs, surgery, and photodynamic therapy. Among these, the surgery segment dominates the US actinic keratosis treatment market with the largest share in 2023. Surgery for actinic keratosis includes cryotherapy, curettage, laser therapy, and photodynamic therapy. Actinic keratosis is removed by freezing the afflicted area with liquid nitrogen, resulting in blistering or peeling in cryotherapy. The increasing demand for total disease eradication is driving the market in the surgery segment.

• The nucleoside metabolic inhibitors segment dominates the market with a significant market share during the forecast period.

The United States actinic keratosis treatment market is segmented by drug class into nucleoside metabolic inhibitors, nonsteroidal anti-inflammatory drugs, immune response modifiers, photoenhancers, and others. Among these, the nucleoside metabolic inhibitors segment dominates the market with a significant market share during the forecast period. Nucleoside metabolic inhibitors such as Efudex, Carac are commonly used to treat actinic keratosis. The increasing need for topical formulations as well as the rising disease awareness are propelling the market growth.

• The 5-fluorouracil segment dominates the US actinic keratosis treatment market during the forecast period.       

Based on the product, the U.S. actinic keratosis treatment market is divided into 5-fluorouracil, diclofenac, imiquimod, tirbanibulin, capecitabine, aminolevulinic acid, porfimer sodium, and others. Among these, the 5-fluorouracil segment dominates the US actinic keratosis treatment market during the forecast period. Fluorouracil is an antimetabolite drug that acts by killing fast-growing cells, including the aberrant ones in actinic keratoses with high clearance rates, and reduces the chance of developing squamous cell carcinoma. The expanding use of this drug in the treatment of actinic keratoses drives the market growth.

• The hospitals segment accounted for the largest revenue share of the US actinic keratosis treatment market in 2023.

The United States actinic keratosis treatment market is segmented by end-use into hospitals, private clinics, homecare, and others. Among these, the hospitals segment accounted for the largest revenue share of the US actinic keratosis treatment market in 2023. Factors such as treatment accessibility, high surgical penetration, and an increase in photodynamic therapy operations performed in hospitals support the market growth. Further, the increasing use of physician-assisted therapies is likely to drive the market in the hospitals segment.   

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the U.S. actinic keratosis treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

List of Key Companies

• Bausch Health Companies, Inc.
• Almirall, S.A
• Sun Pharmaceutical Industries Ltd
• GALDERMA
• Biofrontera AG
• Novartis AG
• LEO Pharma A/S
• 3M
• Hill Dermaceuticals, Inc.
• Viatris, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In February 2021, Almirall, S.A., a global biopharmaceutical company focused on skin health, announced the U.S. commercial launch of Klisyri (tirbanibulin), developed for the topical treatment of actinic keratosis (AK) of the face and scalp. Klisyri was approved by the U.S. Food and Drug Administration (FDA) in December 2020 and is now commercially available.

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United States Actinic Keratosis Treatment Market based on the below-mentioned segments:

US Actinic Keratosis Treatment Market, By Therapy

• Topical/Drugs
• Surgery
• Photodynamic Therapy

US Actinic Keratosis Treatment Market, By Drug Class

• Nucleoside Metabolic Inhibitors
• Nonsteroidal Anti-Inflammatory Drugs
• Immune Response Modifiers
• Photoenhancers
• Others

US Actinic Keratosis Treatment Market, By Product

• 5-Fluorouracil
• Diclofenac
• Imiquimod
• Tirbanibulin
• Capecitabine
• Aminolevulinic Acid
• Porfimer Sodium
• Others

US Actinic Keratosis Treatment Market, By End-Use

• Hospitals
• Private Clinics
• Homecare
• Others